Revenue

Riskified reports its strongest growth in four years, raising its outlook. Our analysis digs past the headlines to the execution behind its AI platform.

Beyond a simple payout, Ituran's latest dividend reveals a robust financial engine, savvy tax strategy, and a deep-seated plan to dominate the future of mobility.

Local Bounti posts 14% revenue growth and narrows losses, but a deep dive into its Q2 financials reveals the high-stakes reality of its path to profitability.

With sales declining, Shoe Station Group taps veteran marketer Tracy Dick. It's a strategic gamble on her ability to overhaul its brands and master omnichannel retail.

A tiny team made a hit show for $4k that drove 25% of a platform's revenue. This isn't a fantasy; it's the new reality of AI-driven entertainment.

Marti Technologies is rapidly expanding its ride-hailing empire across Türkiye. But behind impressive growth numbers lies a complex web of operational risks.

Ituran's stellar Q2 results aren't just about the numbers. They reveal a strategic pivot from vehicle recovery to a diversified, data-driven mobility platform.

Tencent's latest earnings reveal a shocking negative cash flow, driven by a 176% surge in spending. It's a high-stakes gamble on AI to redefine its future.

As BioPorto preps its H1 2026 results, its promising NGAL kidney test faces a crucial moment. Can it sustain growth and appease a global market?

Following its $900M merger, Propelis is moving beyond packaging in South Korea. We analyze its high-stakes strategy to win a $324B market by integrating tech and creative.

Swedish rugged tech firm JLT Mobile Computers posts grim financials, citing AI-driven costs. But a deeper look reveals a strategic pivot to new markets.

Nordic office outfitter Martela issues a stark profit warning, revealing deep market uncertainty and what it means for the future of corporate spending.

Computer Modelling Group reports a 60% profit drop after a major client loss, yet initiates a $20M share buyback. A sign of confidence or a risky gamble?

A traditional construction firm is set to become a pure-play AI robotics company on the NYSE. Why is JFB betting it all on XTEND's autonomous technology?

COSCIENS Biopharma boasts a dramatic financial turnaround, but its strategic move to exit SEC oversight shifts the risk-reward calculus for investors.

Reed's Q2 results show major operational gains and a shrinking net loss, but a steep sales decline and a looming cash crunch raise critical questions.

With a NYSE delisting notice and a dividend under scrutiny, Lument Finance Trust's Q2 report is more than just numbers—it's a test of its strategy.

SINTX Technologies is shifting from R&D to sales, but its ambitious med-tech goals are balanced by a precarious financial reality. Is this a blueprint for resilience?

With FDA clearance for its AI burn scanner, Spectral AI faces its next test: conquering the market. Can it turn government contracts into commercial success?

NeuroPace reports strong Q2 growth and raises 2026 guidance, driven by its RNS system. A new AI tool and key clinical data signal a deeper push into personalized medicine.